|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.84 HKD | +4.67% |
|
+5.49% | +35.54% |
| 24/05 | Organon, Henlius' Denosumab Biosimilar HLX14 Gets European Validation | MT |
| 24/05 | Henlius' EU Marketing Application for Denosumab Biosimilar Accepted and Validated by Regulator | MT |
Shanghai Henlius Biotech, Inc. announced that at the EGM held on July 28, 2022 approved the appointment of Mr. Deyong Wen as a non-executive director of the Company.
| 1st Jan change | Capi. | |
|---|---|---|
| +35.54% | 131.15Cr | |
| -1.64% | 9.03TCr | |
| -1.97% | 3.95TCr | |
| -16.01% | 3.17TCr | |
| +61.28% | 2.64TCr | |
| -22.75% | 1.43TCr | |
| -9.24% | 1.29TCr | |
| -11.77% | 1.18TCr | |
| -45.97% | 1.1TCr | |
| +3.30% | 884.67Cr |
SHANGHAI HENLIUS BIOTECH, INC. 
